Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

Clinical Antipsychotic Trials of Intervention Effectiveness, or CATIE, is a landmark comparative research of four newer atypical antipsychotic medications and one older, conventional one. The largest study of its kind, CATIE reinforces what mental health consumers have said for years: one size does not fit all.

On March 1, 2007, the latest results (Phase 1B) of the Clinical Trials of Intervention Effectiveness (CATIE) Study were released in the American Journal of Psychiatry. Phase 1 and Phase 2 results were previously released in September 2005 in the New England Journal of Medicine and on April 1, 2006 in the American Journal of Psychiatry respectively. 1]

CATIE is the first comprehensive effectiveness study to compare older and newer generation antipsychotic medications. One more phase of this study is expected. To ensure that media, clinician and policymaker interpretation of these and future study results is not misrepresented; Mental Health America has updated its existing materials / resources about the study.

• Press Releases
  - Phase I pdf (September 2005)
  - Phase II pdf (April 2006)
  - Phase 1B (March 2007)

• Fast Facts

• The CATIE Study: Frequently Asked Questions

• The CATIE Study: Separating Fact from Fiction

• The CATIE Study: Issues for Advocates

• CATIE – Primary Resource

  • National Institute of Mental Health: CATIE
  • CATIE website: www.catie.unc.edu
  • Study Findings: The New England Journal of Medicine  pdf
  • Editorial: The New England Journal of Medicine  pdf

For additional information or to speak with an expert or individual with mental illness, please call (703) 797-2588 or email mediainfo@mentalhealthamerica.net.

1Lieberman, J.A. et al. 2005. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine, Vol. 353, No. 12, pp. 1209-1223.